AdAlta Limited (1AD) Fair Value & Analysis
Healthcare · AU · Market cap A$11.2M
Risks
Fair value as of: Aug 26, 2026
From 2 valuation models · updated today
Share price −14.3% over the past month.
Below-average quality, currently priced close to our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price is below even our cautious bear case (A$0.0032). The market is more pessimistic than our downside scenario.
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 26, 2026.
How to read this chart
60‑month range A$0.0020 – A$0.1331 · the A$0.0030 price screens below the A$0.0032 fair value. Dashed = 300-day average. As of Aug 26, 2026.
Analysis
AdAlta Limited (1AD) currently trades at A$0.0030, while our model-based Fair Value estimate is A$0.0032, implying the stock looks roughly 6.7% fairly valued today. The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at A$608K. Revenue declined 18.4% year over year. The balance sheet holds a net cash position of A$1.3M. Fundamentals as of Aug 26, 2026
The share trades about 63% below its 52-week high and 76% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -60% fair-value upside, at 7%, 1AD screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 2 models by family
Notify me when 1AD reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 26, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 27 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics.
Full company description
AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company was incorporated in 2006 and is based in Hawthorn East, Australia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2026 · reported fiscal years
AdAlta Limited reported revenue of A$677K in FY2025 versus A$4.0M in FY2021, a compound −35.8%/yr. Reported net income was −A$4.7M in FY2026.
Watch 1AD: get an alert when its fair value changes →
Peer Group
Biotechnology · 634 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Regeneron Pharmaceuticals, Inc REGN | $797.99 | $594.40 | -26% |
| argenx SE ARGX | €877.60 | €292.84 | -67% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | -77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | -60% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | -69% |
| Moderna, Inc MRNA | $63.67 | $12.77 | -80% |
| BioNTech SE 22UA | €80.60 | €52.92 | -34% |
Compare AdAlta Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is AdAlta Limited (1AD) overvalued or undervalued?
What is the fair value of 1AD?
What is the quality score of 1AD?
What is the revenue of AdAlta Limited (1AD)?
What is the net profit margin of 1AD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track AdAlta Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.